Kidney Cancer Drugs Equal in Prolonging Survival: Study

But pazopanib gives patients a better quality of life than sunitinib, researchers report

HealthDay + More

Most importantly, according to Motzer, patients taking pazopanib rated their quality of life better than patients taking sunitinib.

More information

For more on kidney cancer, visit the American Cancer Society.

Copyright © 2012 HealthDay. All rights reserved.